These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 32676152)

  • 1. Establishing the Structure-Activity Relationship of Daptomycin.
    Chow HY; Po KHL; Jin K; Qiao G; Sun Z; Ma W; Ye X; Zhou N; Chen S; Li X
    ACS Med Chem Lett; 2020 Jul; 11(7):1442-1449. PubMed ID: 32676152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of Action and Resistance to Daptomycin in Staphylococcus aureus and Enterococci.
    Miller WR; Bayer AS; Arias CA
    Cold Spring Harb Perspect Med; 2016 Nov; 6(11):. PubMed ID: 27580748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [In vitro activity of daptomycin against VRE and MRSA strains].
    Aktaş G; Derbentli S
    Mikrobiyol Bul; 2014 Jan; 48(1):123-8. PubMed ID: 24506722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A facile and selective derivatization approach on kynurenine-NH
    Guan D; Li J; Chen F; Li J; Bian X; Yu Y; Feng X; Lan L; Huang W
    Eur J Med Chem; 2023 Nov; 259():115638. PubMed ID: 37482019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging resistance mechanisms for 4 types of common anti-MRSA antibiotics in Staphylococcus aureus: A comprehensive review.
    Liu WT; Chen EZ; Yang L; Peng C; Wang Q; Xu Z; Chen DQ
    Microb Pathog; 2021 Jul; 156():104915. PubMed ID: 33930416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracellular activity of the peptide antibiotic NZ2114: studies with Staphylococcus aureus and human THP-1 monocytes, and comparison with daptomycin and vancomycin.
    Brinch KS; Tulkens PM; Van Bambeke F; Frimodt-Møller N; Høiby N; Kristensen HH
    J Antimicrob Chemother; 2010 Aug; 65(8):1720-4. PubMed ID: 20534628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
    Smith JR; Yim J; Raut A; Rybak MJ
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2352-8. PubMed ID: 26833159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
    McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G
    J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains.
    Rybak MJ; Hershberger E; Moldovan T; Grucz RG
    Antimicrob Agents Chemother; 2000 Apr; 44(4):1062-6. PubMed ID: 10722513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus strains with reduced susceptibility to daptomycin, linezolid or vancomycin, and strains with defined SCCmec types.
    Farrell DJ; Flamm RK; Sader HS; Jones RN
    Int J Antimicrob Agents; 2014 Apr; 43(4):323-7. PubMed ID: 24411474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005).
    Sader HS; Watters AA; Fritsche TR; Jones RN
    BMC Infect Dis; 2007 Apr; 7():29. PubMed ID: 17442104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives.
    Cafini F; Aguilar L; González N; Giménez MJ; Torrico M; Alou L; Sevillano D; Vallejo P; Prieto J
    J Antimicrob Chemother; 2007 Jun; 59(6):1185-9. PubMed ID: 17412725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delafloxacin activity against Staphylococcus aureus with reduced susceptibility or resistance to methicillin, vancomycin, daptomycin or linezolid.
    Saravolatz LD; Pawlak JM; Wegner C
    J Antimicrob Chemother; 2020 Sep; 75(9):2605-2608. PubMed ID: 32542310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daptomycin therapy for invasive Gram-positive bacterial infections in children.
    Ardura MI; Mejías A; Katz KS; Revell P; McCracken GH; Sánchez PJ
    Pediatr Infect Dis J; 2007 Dec; 26(12):1128-32. PubMed ID: 18043450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The global prevalence of Daptomycin, Tigecycline, Quinupristin/Dalfopristin, and Linezolid-resistant Staphylococcus aureus and coagulase-negative staphylococci strains: a systematic review and meta-analysis.
    Shariati A; Dadashi M; Chegini Z; van Belkum A; Mirzaii M; Khoramrooz SS; Darban-Sarokhalil D
    Antimicrob Resist Infect Control; 2020 Apr; 9(1):56. PubMed ID: 32321574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial susceptibility of daptomycin and comparator agents tested against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: trend analysis of a 6-year period in US medical centers (2005-2010).
    Sader HS; Moet GJ; Farrell DJ; Jones RN
    Diagn Microbiol Infect Dis; 2011 Jul; 70(3):412-6. PubMed ID: 21546202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daptomycin - a novel antibiotic against Gram-positive pathogens.
    LaPlante KL; Rybak MJ
    Expert Opin Pharmacother; 2004 Nov; 5(11):2321-31. PubMed ID: 15500379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections.
    Steenbergen JN; Alder J; Thorne GM; Tally FP
    J Antimicrob Chemother; 2005 Mar; 55(3):283-8. PubMed ID: 15705644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Newer treatment options for skin and soft tissue infections.
    Raghavan M; Linden PK
    Drugs; 2004; 64(15):1621-42. PubMed ID: 15257625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci at a university hospital in Taiwan from 1991 to 2003: resistance trends, antibiotic usage and in vitro activities of newer antimicrobial agents.
    Hsueh PR; Chen WH; Teng LJ; Luh KT
    Int J Antimicrob Agents; 2005 Jul; 26(1):43-9. PubMed ID: 15975769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.